The headline safety finding in plain terms

Across more than 19,000 treatments recorded in the manufacturer's Version 09 Clinical Evaluation Report (CER, dated 30 April 2025), ChondroFiller® liquid has produced no serious adverse device effects (SADEs) — meaning no device-related complications requiring significant medical intervention have been identified through the post-market clinical follow-up (PMCF) programme. In everyday terms, the reported complication rate is approximately 0%.

For patients weighing up an injectable treatment, that figure invites an obvious question: is it simply too good to be true? The answer lies in the size of the dataset. At over 19,000 treatments, administered across multiple joint sites — knee, hip, shoulder, ankle, wrist, elbow, foot, and hand — and across different geographic markets, genuinely rare events would be expected to appear in the data if they existed. Their consistent absence across this volume of real-world use provides a statistical foundation for confidence rather than a gap in detection.

It is worth being precise about what this evidence represents. The CER consolidates PMCF studies, prospective cohort data, and registry experience — not blinded randomised controlled trial (RCT) data. That distinction is honest and relevant: the favourable safety picture emerges from observational and post-market sources, all manufacturer-sponsored, with no published active-comparator RCT to date. Patients and clinicians should weigh the signal accordingly — substantial and consistently positive, but drawn from a specific evidence architecture.

Where the 19,000-treatment figure comes from

Three distinct evidence streams feed the CER v09 figure: post-market clinical follow-up (PMCF) studies conducted as part of ChondroFiller®'s regulatory obligations, prospective cohort studies with planned follow-up intervals, and real-world registry data collected across multiple countries. Understanding what each stream represents helps make sense of the safety picture.

PMCF is a legal requirement under the EU Medical Device Regulation (MDR) for any Class III device — the highest-risk classification — once it enters routine clinical use. Unlike a clinical trial, which tests a hypothesis before widespread use, PMCF continuously tracks performance across ordinary practice: which patient populations are treated, how outcomes differ by joint or defect characteristic, and whether any unexpected safety signals emerge over time. It is compulsory, ongoing surveillance rather than a one-off study.

Layered on top of PMCF are the prospective cohort studies and registry data. Registry data captures volume and demographic breadth; cohort studies apply pre-specified outcome measures at defined time points. The cross-market design — evidence drawn from multiple countries with different prescribing cultures — makes it harder to dismiss the favourable safety profile as a product of unusually cautious patient selection in a single healthcare system.

One honest boundary should be noted early: PMCF is a structured regulatory obligation, not a randomised controlled trial. It cannot control for selection effects with the rigour that blinding and randomisation provide. The limitations section returns to this distinction in more detail.

The two risks practitioners take most seriously

Two specific risk categories come up consistently in clinical assessment of ChondroFiller®: the possibility of joint infection following any intra-articular injection, and the immunogenicity implications of the product's murine-derived collagen source. Both are manageable with standard protocols, and understanding each clearly is more useful than treating them as equivalent concerns.

Infection is the most serious theoretical risk attached to any injection placed directly into a joint — not because it is common with ChondroFiller®, but because joint infection carries significant consequences if it does occur. Standard clinical practice includes intravenous (IV) antibiotic cover at the injection appointment as a routine precaution. The CER v09 indicates that ChondroFiller®'s compositional profile — an acellular collagen gel with no permanent implant or foreign particulate — is associated with an infection risk profile lower than that of polyacrylamide hydrogel alternatives; IV antibiotic cover adds a further protective layer on top of that inherent profile.

Immunogenicity is the more nuanced of the two concerns. ChondroFiller® is derived from murine (mouse) Type I collagen and is acellular, meaning no living cells are introduced into the joint. The absence of live cells eliminates the cell-mediated immune responses that can arise with cell-based therapies such as autologous chondrocyte implantation. Type I collagen itself is a well-established structural biomaterial with a long record in tissue engineering and biomedical use. That said, the murine protein source means a small residual risk of allergic reaction cannot be entirely excluded; routine pre-treatment screening is therefore standard practice prior to administration.

Complication and reoperation rates against other cartilage treatments

Numbers tell the clearest part of the story. Across the comparative data consolidated in the CER v09, ChondroFiller® liquid carries a reoperation rate of approximately 3–8% — against microfracture's rate of up to 41% and ACI/MACI's rate of up to 37%. On complications, the gap is similarly wide: ACI/MACI is associated with complications in up to 17% of cases; ChondroFiller®'s reported rate approximates zero across the PMCF dataset.

A brief caveat is warranted. Microfracture, ACI/MACI, and osteochondral autograft transfer (OAT/mosaicplasty) are established procedures with decades of evidence behind them, appropriate for patients whose defect size, joint condition, or clinical circumstances place them outside ChondroFiller®'s indicated range. These figures reflect different risk profiles — not a ranking of procedures by overall quality.

What reoperation rates capture is cumulative exposure to risk. Each return to intervention carries its own anaesthetic, procedural, and recovery burden. A lower reoperation rate therefore means less total harm exposure across a treatment journey, not merely a logistical advantage.

Functional outcome data add a further layer of reassurance. Jerosch et al.'s prospective PMCF study recorded a mean improvement of 32.4 points on the IKDC score — a validated patient-reported measure of knee function — sustained at three-year follow-up, with patients reaching a score of 80. MOCART imaging scores of 81.6 to 84.3 indicate greater than 80% cartilage defect filling with good tissue integration; one cohort showed progressive improvement from 65.3 at four weeks to 81.6 at one year. Neither the functional nor the structural findings are direct safety endpoints, but sustained improvement and progressive scaffold maturation confirm the absence of progressive joint deterioration — a key concern with any injectable biomaterial placed in a load-bearing environment.

Which patients the safety data actually covers

The ~0% serious adverse device effect rate reported across the CER v09 dataset is not a blanket guarantee — it is a finding that applies within defined clinical boundaries, and those boundaries are worth understanding clearly.

The evidence covers patients with focal, contained cartilage defects graded III or IV on the standard scale, measuring no more than 6 cm² and bordered by structurally healthy surrounding cartilage. These are discrete, localised lesions — not the generalised joint-surface deterioration associated with diffuse or end-stage osteoarthritis. For patients with widespread cartilage loss, the published safety and outcome data do not apply; different management pathways would typically be considered.

Data do exist across multiple joint sites, but that breadth does not mean eligibility is assumed — each patient and each joint is assessed individually against these structural criteria before treatment is considered.

This framing is not a gatekeeping exercise. It reflects how evidence-based medicine works: the published safety profile is strong precisely because the studies enrolled patients who met clearly defined criteria. A structured specialist consultation is the route to establishing whether those criteria are met in any individual case.

Honest gaps in the evidence

Three caveats sit underneath the numbers in this article, and the most important concerns independence.

The CER v09 is manufacturer-consolidated. The clinical data have not yet been replicated by research groups with no commercial stake in the outcome — that is a genuine limitation, not an implication of misconduct. PMCF data collection is a regulatory requirement under EU MDR, but the evidence base remains internally generated. No published randomised controlled trial has compared ChondroFiller® against an active treatment comparator under blinded, controlled conditions.

PMCF designs are also not blinded. The ~0% serious adverse device effect figure is a meaningful signal across a large real-world dataset; it does not carry the same evidentiary weight as a finding produced under randomised conditions.

Neither caveat erases what 19,000 treatments across eight joint sites and multiple countries actually shows: no pattern of serious device-related harm has emerged. The honest distinction for any patient considering this pathway is that the signal is large and consistent, and the methodology is observational. Those two things can be true simultaneously — and the 3–8% reoperation rate, even on registry evidence, remains well below every surgical comparator reviewed in this article.